Is CJC-1295 with ipamorelin and GHRP-2 legal in Australia?

Three growth hormone secretagogues in one vial, commonly 2 mg each in a 6 mg vial. Two of the three act at exactly the same receptor, which is the fact this product is built to obscure. The combination has never been studied, and adding a second ghrelin-receptor agonist to the first adds the older agent's appetite and cortisol profile without adding a second mechanism.

Three is the number that should stop a buyer. Ipamorelin and GHRP-2 are both agonists at the growth hormone secretagogue receptor, the ghrelin receptor.

Mechanism: Two of the three components are agonists at the same growth hormone secretagogue receptor and are additive at that receptor rather than complementary. The third is a GHRH receptor agonist raising pulse amplitude.

Regulatory history: Not approved. None of the three components is an approved medicine in the United States and no regulator has evaluated any combination of them.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for CJC-1295 with ipamorelin and GHRP-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.